The case for & against
Bull & Bear analysis
Legend Biotech (NASDAQ: LEGN) is an innovative biopharmaceutical company specializing in CAR-T cell therapies, with a prominent focus on its flagship product, Carvicti, designed to treat multiple myeloma. Positioned as a leading player in the emerging cell therapy space, Legend Biotech has developed a strong pipeline and operational framework to address significant unmet medical needs across various oncology indications. With a robust partnership with Johnson & Johnson, the company aims to expand its global market presence while enhancing its R&D capabilities, underscoring its commitment to transforming cancer care through advanced therapies.
Bull says
- ↑Q1 2026 Carvicti net trade sales $597M, +62% YoY
- ↑FDA removed REMS for Carvicti, enhancing patient access
- ↑Cash and equivalents of $835M provide runway for growth
- ↑66% of oncologists willing to prescribe Carvicti at first relapse
- ↑~100k multiple myeloma patients, only 5% treated with CAR-T
- ↑Strong growth and revision factors plus low leverage signal resilience
Bear says
- ↓Q1 net loss $11M vs. $27M year-ago, profitability still elusive
- ↓Gross margin fell to 41% from 57% due to manufacturing ramp costs
- ↓Intensifying competition and emerging bispecifics may erode market share
- ↓High short interest reflects investor skepticism on performance
- ↓Onboarding community oncology sites remains challenging and scaling risk
- ↓Negative profitability factors and low momentum may deter new investors
Investment themes with LEGN
High-growth market driven by manufacturing and consumption
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- issued a press release announcing our financial results for the quarter.
- highly confident that we will be able to achieve the superiority against RBD in this specific patient population.
- we remain highly confident that will demonstrate superiority in TFS compared to RBD.
Bear points
- J&J recently announced that they discontinued the development program for the dual targeting mechanism.
- J&J recently announced that they discontinued the development program for the dual targeting mechanism.
- The decline from the fourth quarter at 57% was primarily due to one-time expenses associated with ramping up manufacturing in the newly expanded section of our Raritan site and the ongoing Tech Lane facility ramp.